A study of the effects of OC000459 on responses to allergen challenge in the Vienna Chamber in subjects known to suffer from grass pollen induced allergic rhinitis: A randomised, double blind placebo controlled, two way crossover evaluation of a dose schedule of 200 mg given twice daily orally for eight days in male subjects.

Trial Profile

A study of the effects of OC000459 on responses to allergen challenge in the Vienna Chamber in subjects known to suffer from grass pollen induced allergic rhinitis: A randomised, double blind placebo controlled, two way crossover evaluation of a dose schedule of 200 mg given twice daily orally for eight days in male subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs OC 459 (Primary)
  • Indications Allergic rhinoconjunctivitis; Grass pollen hypersensitivity
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2011 Additional trial location (Austria) added as reported by ClinicalTrials.gov.
    • 06 Oct 2011 Additional lead trial investigator (Friedrich Horak) identified as reported by ClinicalTrials.gov.
    • 06 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top